Long‐term outcome of dietary therapy in primary intestinal lymphangiectasia: Are we achieving sustained remission? A national retrospective study
Journal of Pediatric Gastroenterology and Nutrition · 18.11.2026
DOI: 10.1002/jpn3.70690 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, online erschienen am 18.11.2026. Verfasst von Sara Renzo und 10 weiteren Autor:innen. Die Arbeit nennt 17 Literaturangaben.
Abstract (Originalsprache)
Objectives
Primary intestinal lymphangiectasia (PIL) is a rare congenital malformation causing protein‐losing enteropathy. Given limited data on long‐term dietary outcomes, this study describes clinical features, dietary response durability, and second‐line therapies in an Italian pediatric cohort.
Methods
This multicenter retrospective study (2012–2025) analyzed children with PIL. Complete clinical remission required symptom resolution, normalized serum albumin, and intravenous albumin independence. Endoscopic and histological remissions were defined as the absence of macroscopic alterations and lymphatic vessel dilatation, respectively.
Results
Eighteen patients were included (median onset/diagnosis: 9 and 16 months, respectively). Key symptoms were ascites (82.4%), peripheral edema (76.5%), and lymphedema (64.7%); 94.1% showed profound hypoalbuminemia, hypoproteinemia, and hypogammaglobulinemia. Endoscopy revealed “snowflake” mucosa in 86.7%. Although all started a low‐fat, high‐protein medium‐chain triglycerides diet, only 27.7% (5/18) achieved sustained complete remission on diet alone. Due to dietary failure, 55.6% (10/18) required second‐line treatments (octreotide, sirolimus), with limited remission rates (1/4 and 2/7, respectively); one refractory child achieved remission with everolimus after sirolimus failure. At a median 5‐year follow‐up, endoscopic and histological remissions were reached in 54.5% (6/11) and 57.1% (4/7) of re‐evaluated patients.
Conclusions
PIL poses significant therapeutic challenges. Our findings show a loss of response to dietary management over time in a subset of patients, requiring tailored second‐line pharmacological interventions whose management currently relies on limited clinical experiences in refractory cases.
Zitieren
APA
Renzo, S., Naldini, S., Dalpiaz, I., Scarallo, L., Chiaro, A., Crocco, M., Diamanti, A., Romano, C., Labriola, F., Norsa, L., & Lionetti, P. (2026). Long‐term outcome of dietary therapy in primary intestinal lymphangiectasia: Are we achieving sustained remission? A national retrospective study. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/jpn3.70690
Vancouver
Renzo S, Naldini S, Dalpiaz I, Scarallo L, Chiaro A, Crocco M, et al. Long‐term outcome of dietary therapy in primary intestinal lymphangiectasia: Are we achieving sustained remission? A national retrospective study. Journal of Pediatric Gastroenterology and Nutrition. 2026. doi:10.1002/jpn3.70690
BibTeX
@article{Renzo2026,
author = {Renzo, Sara and Naldini, Sara and Dalpiaz, Irene and Scarallo, Luca and Chiaro, Andrea and Crocco, Marco and Diamanti, Antonella and Romano, Claudio and Labriola, Flavio and Norsa, Lorenzo and Lionetti, Paolo},
title = {Long‐term outcome of dietary therapy in primary intestinal lymphangiectasia: Are we achieving sustained remission? A national retrospective study},
journal = {Journal of Pediatric Gastroenterology and Nutrition},
year = {2026},
doi = {10.1002/jpn3.70690}
}
EUVIMED